Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1057004

registered interest
date	08/02/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Breast Cancer: Health Professions
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if the Government will commit to fully funding the Workforce Implementation Plan to tackle shortages in the breast cancer workforce.
tabling member constituency	Crewe and Nantwich
tabling member printed	Laura Smith
uin	218843
answer	answer is ministerial correction date of answer 18/02/2019 answer text <p>My Rt. hon. Friend the Secretary of State for Health and Social Care has commissioned Baroness Dido Harding, working closely with Sir David Behan, to lead a number of programmes to engage with key National Health Service interests to develop a detailed workforce implementation plan. These programmes will consider detailed proposals to grow the workforce rapidly, including the breast cancer workforce, consider additional staff and skills required, build a supportive working culture in the NHS and ensure first rate leadership for NHS staff.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 18/02/2019 17:30:42 answering member 4067 label Biography information for Steve Brine
tabling member	4648 label Biography information for Laura Smith

1057018

registered interest
date	08/02/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Pancreatic Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure that every patient with pancreatic cancer receives treatment within the first 20 days of diagnosis.
tabling member constituency	Birmingham, Selly Oak
tabling member printed	Steve McCabe
uin	218748
answer	answer is ministerial correction date of answer 18/02/2019 answer text <p>The information is not available in the format requested.</p><p> </p><p>Clinical priority remains the main determinant of when a patient should be treated.</p><p> </p><p>NHS England will shortly be introducing a new Faster Diagnostic Standard for all cancer patients, including those with suspected pancreatic cancer, which will see patients given a diagnosis or the all clear within 28 days. The 31-day standard of decision to treat to undergoing first treatment will remain in place. However, this is an upper limit and clinical priority will always remain the main determinant of when a patient should be treated.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 218749 question first answered 18/02/2019 17:29:51 answering member 4067 label Biography information for Steve Brine
tabling member	298 label Biography information for Steve McCabe

1057020

registered interest
date	08/02/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Pancreatic Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many pancreatic cancer patients received treatment within 20 days of diagnosis in each of the last five years.
tabling member constituency	Birmingham, Selly Oak
tabling member printed	Steve McCabe
uin	218749
answer	answer is ministerial correction date of answer 18/02/2019 answer text <p>The information is not available in the format requested.</p><p> </p><p>Clinical priority remains the main determinant of when a patient should be treated.</p><p> </p><p>NHS England will shortly be introducing a new Faster Diagnostic Standard for all cancer patients, including those with suspected pancreatic cancer, which will see patients given a diagnosis or the all clear within 28 days. The 31-day standard of decision to treat to undergoing first treatment will remain in place. However, this is an upper limit and clinical priority will always remain the main determinant of when a patient should be treated.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 218748 question first answered 18/02/2019 17:29:51 answering member 4067 label Biography information for Steve Brine
tabling member	298 label Biography information for Steve McCabe

1057021

registered interest
date	08/02/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cancer: Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether the Government has made an assessment of the level of funding required by Cancer Alliances to deliver the policies set out in the NHS Long Term Plan.
tabling member constituency	Mitcham and Morden
tabling member printed	Siobhain McDonagh
uin	218743
answer	answer is ministerial correction date of answer 18/02/2019 answer text <p>Cancer Alliances will work with their sustainability and transformation plans/integrated care systems to develop local plans that set out how they will direct local funding to deliver the cancer ambitions in the NHS Long Term Plan. Cancer Alliances will receive funding to support the transformation required to address the priorities for their local populations.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 18/02/2019 17:16:22 answering member 4067 label Biography information for Steve Brine
tabling member	193 label Biography information for Dame Siobhain McDonagh

1057028

registered interest
date	08/02/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Incinerators: Air Pollution
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 5 February 2019 to Question 213202 on Incinerators: Air Pollution, with reference to the report entitled Ultrafine Particulates (UFP) in the UK, published by the Air Quality Expert Group by his Department in 2018, if he will make an assessment of the effect of ultrafine particles on human health (a) in and (b) outside of the vicinity of incinerators.
tabling member constituency	Stroud
tabling member printed	Dr David Drew
uin	218744
answer	answer is ministerial correction date of answer 18/02/2019 answer text <p>The Air Quality Expert Group Report on ‘Ultrafine Particles in the UK’ summarised current knowledge on the levels, sources and characteristics of ultrafine particles in the United Kingdom air; the report can be viewed at the following link:</p><p> </p><p><a href="https://uk-air.defra.gov.uk/library/reports.php?report_id=968" target="_blank">https://uk-air.defra.gov.uk/library/reports.php?report_id=968</a></p><p> </p><p>An assessment on the potential health impacts of ultrafine particles was beyond the scope of this report.</p><p> </p><p>Reviews by the Health Effects Institute and World Health Organization of the effects of different components of air pollution, including ultrafine particles (PM<sub>0.1</sub>), concluded that there is currently limited evidence on the effects on health of ultrafine particles. These reports are available to view at the following links:</p><p> </p><p><a href="https://www.healtheffects.org/publication/understanding-health-effects-ambient-ultrafine-particles" target="_blank">https://www.healtheffects.org/publication/understanding-health-effects-ambient-ultrafine-particles</a></p><p> </p><p><a href="http://www.euro.who.int/__data/assets/pdf_file/0004/193108/REVIHAAP-Final-technical-report-final-version.pdf?ua=1" target="_blank">http://www.euro.who.int/__data/assets/pdf_file/0004/193108/REVIHAAP-Final-technical-report-final-version.pdf?ua=1</a></p><p> </p><p>Public Health England has no plans to engage in work on the effects of ultrafine particles on human health in and outside the vicinity of incinerators.</p><p><strong> </strong></p> answering member constituency Winchester answering member printed Steve Brine question first answered 18/02/2019 17:27:43 answering member 4067 label Biography information for Steve Brine
tabling member	252 label Biography information for Dr David Drew

1057029

registered interest
date	08/02/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Incinerators: Air Pollution
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 5 February 2019 to Question 213203 on Incinerators: Air Pollution, if he will publish the results of the developing work referred to in paragraph 15 of the paper, The Impact on Health of Emissions to Air from Municipal Waste Incinerators, published in September 2009.
tabling member constituency	Stroud
tabling member printed	Dr David Drew
uin	218745
answer	answer is ministerial correction date of answer 18/02/2019 answer text <p>Paragraph 15 of the report ‘The Impact on Health of Emissions to Air from Municipal Waste Incinerators’ refers to ultrafine particles. The report can be viewed at the following link:</p><p> </p><p><a href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/384592/The_impact_on_health_emissions_to_air_from_municipal_waste_incinerators.pdf" target="_blank">https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/384592/The_impact_on_health_emissions_to_air_from_municipal_waste_incinerators.pdf</a></p><p> </p><p>Since this report, the reviews by the Health Effects Institute and World Health Organization of the effects of different components of air pollution, including ultrafine particles (PM<sub>0.1</sub>), concluded that there is currently limited evidence on the effects on health of ultrafine particles. These reviews can be viewed at the following links:</p><p> </p><p><a href="https://www.healtheffects.org/publication/understanding-health-effects-ambient-ultrafine-particles" target="_blank">https://www.healtheffects.org/publication/understanding-health-effects-ambient-ultrafine-particles</a></p><p> </p><p><a href="http://www.euro.who.int/__data/assets/pdf_file/0004/193108/REVIHAAP-Final-technical-report-final-version.pdf?ua=1" target="_blank">http://www.euro.who.int/__data/assets/pdf_file/0004/193108/REVIHAAP-Final-technical-report-final-version.pdf?ua=1</a></p><p> </p><p>Recent assessments have been undertaken of the health effects of long-term exposure to the air pollution mixture in the United Kingdom. This work estimated that long-term exposure to the man-made air pollution mixture in the UK has an annual effect equivalent to 28,000 to 36,000 deaths. This was based on studies reporting associations of mortality risk with fine particulate matter (PM<sub>2.5</sub>), which includes PM<sub>0.1</sub>, and nitrogen dioxide (NO<sub>2</sub>). These documents can be viewed at the following links:</p><p> </p><p><a href="https://www.gov.uk/government/publications/nitrogen-dioxide-effects-on-mortality" target="_blank">https://www.gov.uk/government/publications/nitrogen-dioxide-effects-on-mortality</a></p><p> </p><p><a href="https://www.gov.uk/government/publications/nitrogen-dioxide-effects-on-mortality" target="_blank">https://www.gov.uk/government/publications/nitrogen-dioxide-effects-on-mortality</a></p><p> </p><p> </p> answering member constituency Winchester answering member printed Steve Brine question first answered 18/02/2019 17:26:09 answering member 4067 label Biography information for Steve Brine
tabling member	252 label Biography information for Dr David Drew

1057030

registered interest
date	08/02/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Plastics: Air Pollution
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what information his Department holds on the pollutants emitted by the combustion of plastic that are detrimental to human health.
tabling member constituency	Stroud
tabling member printed	Dr David Drew
uin	218746
answer	answer is ministerial correction date of answer 18/02/2019 answer text <p>Public Health England (PHE) does not hold specific information on pollutants emitted by the combustion of plastics other than monitoring information provided to it in relation to incidents involving the combustion of plastics, such as fires at centres storing plastics intended for recycling.</p><p> </p><p>PHE, previously as the Health Protection Agency, reviewed the evidence on the products of combustion from fires in general including, but not specifically involving plastics. This advice can be viewed at the following link:</p><p> </p><p><a href="https://www.gov.uk/government/publications/combustion-products-a-toxicological-review" target="_blank">https://www.gov.uk/government/publications/combustion-products-a-toxicological-review</a></p><p> </p><p>The combustion of plastic material can release various substances that are potentially harmful to health, for example, asphyxiant gases e.g. carbon monoxide, irritant gases e.g. hydrogen chloride and phosgene, polychlorinated dibenzo-p-dioxins (PCDDs) and polychlorinated dibenzofurans (PCDFs), phosphorous oxides and particulate matter.</p><p> </p><p>Prediction of the formation toxic combustion products from plastics and risk to health would depend on many factors, such as the type of plastic, combustion conditions (temperature, oxygen availability etc), chemicals released, concentrations and duration of exposure.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 18/02/2019 17:28:53 answering member 4067 label Biography information for Steve Brine
tabling member	252 label Biography information for Dr David Drew

1057031

registered interest
date	08/02/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Air Pollution: Health Hazards
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 4 February 2019 to Question 212585 on Air Pollution: Health Hazards, what steps (a) his Department and (b) Public Health England are taking to compile sufficient evidence to enable further quantification.
tabling member constituency	Stroud
tabling member printed	Dr David Drew
uin	218747
answer	answer is ministerial correction date of answer 18/02/2019 answer text <p>The Committee on the Medical Effects of Air Pollutants (COMEAP) work programme is agreed annually to ensure this meets changing priorities. The committee is not scheduled to engage in further work on the differential health effects of particulate air pollution according to source or components. The Committee’s work programme is reviewed annually to ensure that the work is based on existing priorities. Current topics being considered by COMEAP are available at the following link:</p><p> </p><p><a href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/653713/COMEAP_work_program.pdf" target="_blank">https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/653713/COMEAP_work_program.pdf</a></p><p> </p><p>Recent assessments have been undertaken of the health effects of long-term exposure to the air pollution mixture in the United Kingdom. This was based on studies reporting associations of mortality risk with fine particulate matter (PM<sub>2.5</sub>) and nitrogen dioxide (NO<sub>2</sub>). Further information is available at the following link:</p><p> </p><p><a href="https://www.gov.uk/government/publications/nitrogen-dioxide-effects-on-mortality" target="_blank">https://www.gov.uk/government/publications/nitrogen-dioxide-effects-on-mortality</a></p><p> </p><p>Recent reviews by the Health Effects Institute and World Health Organization of the effects of different components of air pollution, including ultrafine particles (PM0.1), concluded that there is currently limited evidence on the effects on health of ultrafine particles. These reviews can be viewed at the following links:</p><p> </p><p><a href="https://www.healtheffects.org/publication/understanding-health-effects-ambient-ultrafine-particles" target="_blank">https://www.healtheffects.org/publication/understanding-health-effects-ambient-ultrafine-particles</a></p><p> </p><p><a href="http://www.euro.who.int/__data/assets/pdf_file/0004/193108/REVIHAAP-Final-technical-report-final-version.pdf?ua=1" target="_blank">http://www.euro.who.int/__data/assets/pdf_file/0004/193108/REVIHAAP-Final-technical-report-final-version.pdf?ua=1</a></p> answering member constituency Winchester answering member printed Steve Brine question first answered 18/02/2019 17:31:47 answering member 4067 label Biography information for Steve Brine
tabling member	252 label Biography information for Dr David Drew

1056732

registered interest
date	07/02/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Lumacaftor/ivacaftor
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what progress his Department has made on securing the availability of Orkambi on the NHS for patients with cystic fibrosis.
tabling member constituency	Sheffield, Brightside and Hillsborough
tabling member printed	Gill Furniss
uin	218344
answer	answer is ministerial correction date of answer 12/02/2019 answer text <p>The National Institute for Health and Care Excellence (NICE) and NHS England are leading the dialogue with Vertex Pharmaceuticals around access to their portfolio of cystic fibrosis medicines. It is critical that Vertex now re-engages fully with the NICE appraisal process and gives serious consideration to the portfolio deal offer that NHS England made at the end of July. This deal would provide immediate access for patients to all Vertex licensed medicines and future pipeline products once licensed and in advance of the individual NICE appraisals concluding.</p><p> </p><p>The Government fully supports the approach that NICE and NHS England are adopting. It is crucial that patients have access to the most effective and innovative medicines at a price that represents value to the National Health Service.</p><p> </p><p>NHS England has proposed its best offer ever for a drug. This offer, in the region of £500 million over five years, is the largest ever commitment of its kind in the 70-year history of the NHS and would guarantee immediate and expanded access to both Orkambi and the drug Kalydeco for patients who need it. Whilst it is disappointing that Vertex has not taken up NHS England’s offer, we are encouraged that there is continued dialogue between all parties.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 12/02/2019 15:33:24 answering member 4067 label Biography information for Steve Brine
tabling member	4571 label Biography information for Gill Furniss

1056733

registered interest
date	07/02/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cystic Fibrosis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure the NHS is able to offer all treatment options for patients with cystic fibrosis.
tabling member constituency	Sheffield, Brightside and Hillsborough
tabling member printed	Gill Furniss
uin	218345
answer	answer is ministerial correction date of answer 12/02/2019 answer text <p>Specialised services for the support and treatment of patients with cystic fibrosis (CF) are commissioned nationally by NHS England. CF services are delivered in about 20 Paediatric Cystic Fibrosis Centres and about 20 Adult Cystic Fibrosis Centres. There are separate service specifications for adults and children. These specifications are important in clearly defining what NHS England expects to be in place for providers to offer evidence-based, safe and effective care and treatment. The support equity of access to a nationally consistent, high quality service.</p><p> </p><p>The specifications can be found via the following links:</p><p> </p><p><a href="http://www.england.nhs.uk/wp-content/uploads/2018/08/Cystic-fibrosis-adult.pdf" target="_blank">www.england.nhs.uk/wp-content/uploads/2018/08/Cystic-fibrosis-adult.pdf</a></p><p> </p><p><a href="http://www.england.nhs.uk/wp-content/uploads/2018/07/a01Sb-spec-cystic-fibrosis-child.pdf" target="_blank">www.england.nhs.uk/wp-content/uploads/2018/07/a01Sb-spec-cystic-fibrosis-child.pdf</a></p><p> </p><p>In October 2017, the National Institute for Health and Care Excellence (NICE) published new guidance for the diagnosis and management of CF. This includes specific details on how to monitor the condition and manage the symptoms to improve quality of life. This guidance can be found via the following link:</p><p> </p><p><a href="http://www.nice.org.uk/guidance/ng78" target="_blank">www.nice.org.uk/guidance/ng78</a></p><p> </p><p>NICE is the organisation responsible for assessing the clinical and cost effectiveness of medicines for the National Health Service.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 12/02/2019 15:53:01 answering member 4067 label Biography information for Steve Brine
tabling member	4571 label Biography information for Gill Furniss